Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC9 | O60706 | 9/20 | 0.50 |
| ▸ | ABCC8 | Q09428 | 9/20 | 0.50 |
| ▸ | KCNJ11 | Q14654 | 9/20 | 0.50 |
| ▸ | KCNJ8 | Q15842 | 9/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | GPR174 | Q9BXC1 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.44 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.44 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7814727 | 0.92 | ABCC9 (0.60) | ABCC9ABCC8KCNJ11KCNJ8KMT2A | |
| SCHEMBL7097522 | 0.91 | ABCC9 (0.57) | ABCC9ABCC8KCNJ11KCNJ8KMT2A | |
| SCHEMBL6908037 | 0.87 | KMT2A (0.43) | ABCC9ABCC8KCNJ11KCNJ8KMT2A | |
| SCHEMBL6908767 | 0.85 | MEN1 (0.44) | ABCC9ABCC8KCNJ11KCNJ8KMT2A | |
| SCHEMBL7835693 | 0.84 | ABCC9 (0.52) | ABCC9ABCC8KCNJ11KCNJ8KMT2A | |
| SCHEMBL7817217 | 0.83 | CA1 (0.60) | KMT2AMEN1TDP1CA12CA1 | |
| SCHEMBL8741586 | 0.82 | KMT2A (0.43) | ABCC9ABCC8KCNJ11KCNJ8KMT2A | |
| SCHEMBL6436430 | 0.81 | MEN1 (0.48) | ABCC9ABCC8KCNJ11KCNJ8KMT2A | |
| SCHEMBL6904653 | 0.81 | MEN1 (0.48) | ABCC9ABCC8KCNJ11KCNJ8KMT2A | |
| SCHEMBL7095697 | 0.80 | CACNA1C (0.62) | ABCC9ABCC8KCNJ11KCNJ8LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2003517454-A | — | — | 2003-05-27 | — | — | JP | claimed |
| US-6518279-B2 | For treatment of asthma, epilepsy, hypertension, impotence, migraine, pain, urinary incontinence, stroke, Raynaud's syndrome, eating disorders, functional bowel disorders, and neurodegeneration; inotropic agents | ABBOTT LABORATORIES | 2003-02-11 | — | — | US | claimed |
| US-20020007065-A1 | CYCLOPENTANONE DIHYDROPYRIDINE COMPOUNDS USEFUL AS POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES | 2002-01-17 | — | — | US | claimed |
| EP-1075466-A1 | CYCLOPENTANONE DIHYDROPYRIDINE COMPOUNDS USEFUL AS POTASSIUM CHANNEL OPENERS | Abbott Laboratories (US) | 2001-02-14 | — | — | EP | claimed |
| WO-2000051986-A1 | CYCLOPENTANONE DIHYDROPYRIDINE COMPOUNDS USEFUL AS POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2000-09-08 | — | — | WO | claimed |
| US-6518279-B2 | For treatment of asthma, epilepsy, hypertension, impotence, migraine, pain, urinary incontinence, stroke, Raynaud's syndrome, eating disorders, functional bowel disorders, and neurodegeneration; inotropic agents | ABBOTT LABORATORIES | 2003-02-11 | — | — | US | disclosed |
| US-20020007065-A1 | CYCLOPENTANONE DIHYDROPYRIDINE COMPOUNDS USEFUL AS POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES | 2002-01-17 | — | — | US | disclosed |
| EP-1075466-A1 | CYCLOPENTANONE DIHYDROPYRIDINE COMPOUNDS USEFUL AS POTASSIUM CHANNEL OPENERS | Abbott Laboratories (US) | 2001-02-14 | — | — | EP | disclosed |
| WO-2000051986-A1 | CYCLOPENTANONE DIHYDROPYRIDINE COMPOUNDS USEFUL AS POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2000-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020007065-A1 | CYCLOPENTANONE DIHYDROPYRIDINE COMPOUNDS USEFUL AS POTASSIUM CHANNEL OPENERS | KCNN1, KCNJ2, KCNH1 | ABCC9 416/4885ABCC8 743/4885KCNJ11 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.